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Epilepsy is a chronic neurological disorder cha-
racterized by seizures that result from a sudden, disor-
derly depolarisation of neurons in the brain (1). Many
patients with epilepsy fail to effectively control their
seizure, despite of optimal usage of the available anti-
epileptic drugs. In other patients, such a control is possi-
ble at the expense of significant toxic side-effects (2).
Therefore, new anticonvulsant drugs with enhanced ef-
ficacy and minimal side-effects need to be developed.
One of the classes of compounds with well do-
cumented anticonvulsant activity are succinimide
derivatives (3-7), and their 3-spirocycloalkyl analo-
gues (8-10). Structure-activity relationship studies
show that the anticonvulsant properties of this class
are associated with the presence of carbonyl groups,
important for hydrogen binding, as well as with li-
pophilic aryl portion facilitating penetration of the
blood-brain barrier (11-13). This aromatic fragment
is connected with imide moiety at position -3 and/or
at the imide nitrogen atom.
In our earlier study we described anticonvulsant
activity of a great number of succinimides with dif-
ferent substituents at the nitrogen atom and at posi-
tion -3 of pyrrolidine-2,5-dione ring (14-16). The
most promising were compounds with an aromatic
ring at position -3 of the imide moiety, and a pyridyl,
or phenyl substituent at the imide nitrogen atom.
It was also found that the kind and position of substi-
tuents in the aromatic area had a significant effect on
the activity of those compounds. (17, 18). The struc-
tures of the active compounds are presented below:
comp. I
ASP class 1 (30mg/kg MES)
comp. II
ASP class 1 (30mg/kg MES)
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Abstract: As part of our study, a series of N-phenyl- and N-benzyl-bicyclo [2.2.1] hept-5-ene-2,3-dicarboximi-
des [III-XVI], structurally related to the previously described N-phenyl- or N-pirydyl-3-arylpyrrolidine-2,5-
dione [I, II], were synthesized and tested for their anticonvulsant activity in the maximum electroshock seizu-
re (MES) and metrazole seizure threshold (sc. MET) tests. The most potent in the maximum electroshock se-
izure (MES) test were compounds with methyl [III] and chloro [XI] substituents at position -2 of the aromatic
ring, whereas of all the synthesized compounds, only N-(2-methoxybenzyl)-bicyclo [2.2.1] hept-5-ene-2,3-di-
carboximide [XII] was active in the sc. MET. Compounds with substituents at position -3 or -4 of the aroma-
tic ring were found to be less active [V, VI, XIII and XIV], or devoid of activity [VII, IX, XV and XVI]. In
contrast, the N-(4-chlorophenyl)-bicyclo [2.2.1] hept-5-ene-2,3-dicarboximide [VIII] at a dose of 100mg/kg
was active in the MES test.
Keywords: N-phenyl- and N-benzyl-bicyclo [2.2.1] hept-5-ene-2,3-dicarboximides; succinimide; pyrrolidine-
-2,5-dione; anticonvulsant activity
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The obtained results prompted us to synthesize
a variety of N-phenyl- [III-IX] and N-benzyl- [X-
-XVI] analogues of bicyclo [2.2.1] hept-5-ene-2,3-
dicarboximide in which succinimide is a basic struc-
ture. We assumed that such modification, as well as
introduction of different substituents to the aryl ring
would yield compounds with more potent anticon-
vulsant activity.
The final dicarboximides [III-XVI] were syn-
thesized using standard literature methods (4, 19,
20) as outline in Scheme 1. This reaction was perfor-
med by treatment of bicyclo [2.2.1] hept-5-ene-2,3-
dicarboxylic anhydride with an appropriate phenyl
or benzylamine, and further heating of obtained so-
lid residues with acetic anhydride and sodium aceta-
te at 90-950C for 1 h. 
1H NMR spectra of the synthesized compounds
were studied. 
The 1H NMR spectra of the investigated com-
pounds revealed a few characteristic chemical shifts
(see Tables 2 and 3). The chemical shifts of the nor-
bornane protons Ha in all the compounds were shown
as multiplets within the range δ 1.51-1.87 ppm. The
resonance signals of protons of the norbornane ring
Hb, and Hc appeared as multiplets within the range δ
3.25-3.57 ppm. The signals of double bond (Hd) pro-
tons were observed as a doublet of triplets within the
range δ 6.32-6.36ppm [IV] and as triplets ranging
from δ 5.89 ppm to δ 6.35 ppm [III, V-XVI]. The
protons of the -CH2- group appeared as singlets at δ
4.45-4.68 ppm [X-XVI]. The resonance signals of
-CH3 protons were recorded as doublets within the
range δ 2.08-2.17 ppm for compounds with the me-
thyl group at the ortho position of the aryl ring [III,
IV], and as singlets at δ 2.39 ppm [VII] and δ 2.34
[XV] for the para isomers. The protons of the -OCH3
group of compounds XII and XVI appeared as sin-
glets at δ 3.86ppm and δ 3.81ppm, respectively. The
resonance signals of aromatic protons [III-XVI] we-
re well-separated and were observed ranging from δ
6.80ppm to δ 7.66 ppm. Their position depend on the
kind of substituents in the aryl ring. For the details
see Tables 2 and 3.
The 1H-NMR spectral data supported the che-
mical structure of compounds III-XVI.
EXPERIMENTAL
Chemistry
Melting points (m. p. 0C) were determined with
an Electrothermal digital melting point apparatus
and are uncorrected. The chemical structure of the
obtained compounds was confirmed by elemental
and spectral analyses. 1H NMR spectra (in CDCl3)
were obtained in a Varian Mercury spectrometer
working at 300 MHz. Chemical shifts were descri-
bed as parts per million (δ ppm) from (CH3)4Si
(TMS) as an internal standard. Signal multiplicities
are represented by the following abbreviations: s
(singlet), d (doublet), dd (doublet of doublets), td
(triplet of doublets), t (triplet), dt (doublet of tri-
plets), m (multiplet).
Elemental analyses for C, H, N were within ±
0.4% of the theoretical values.
The purity of the compounds was checked by
thinñlayer chromatography (TLC) performed on
Merck silica gel GF254 aluminium sheets using the
following developing systems: A) chloroform: ace-
tone (9: 1), B) ethyl acetate: hexane (3: 7). Spots we-
re detected under UV light (λ = 254 nm).
GENERAL PROCEDURE FOR THE PREPARA-
TION OF N-PHENYL AND N-BENZYL BICYC-
LO [2.2.1] HEPT-5-ENE-1,3-DICARBOXIMIDES
[III-XVI].
To a solution of bicyclo [2.2.1] hept-5-ene-2,3-
dicarboxylic anhydride (0.01 mole) in ethyl acetate
(10 mL) an appropriately substituted phenyl- or ben-
zyl- amine (0.01 mole) in ethyl acetate (10 mL) was
added and left at room temperature for 12 h. After
that time, crystalline products were formed. The ob-
tained solid residues were filtered and crystallized
from isopropanol. The final dicarboximides [III-
-XVI] were prepared by heating of the above residu-
es with an acetic anhydride (10 mL) and a catalytic
amount of anhydrous sodium acetate (0.5 g) in a wa-
ter bath for 1 h. After that time, the products were
cooled and ice water was added. The mixtures were
left overnight in a refrigerator. The crude products
were filtered and purified by crystallization from
methanol. The physicochemical data, yields, ele-
mental analyses and Rf values are presented in Table
1. The 1H NMR spectral data are shown in Tables 2
and 3.
Pharmacology
All the obtained compounds were pharmacolo-
gically pre-evaluated within the Antiepileptic Drug
Development (ADD) Program, (Epilepsy Branch,
Neurological Disorders Program, National Institute
of the Neurological and Communicative Disorders
and Stroke (NINCDS), Bethesda) using the test pro-
cedures described elsewhere (21, 22). Phase I stu-
dies of the investigated compounds involved three
tests: maximal electroshock (MES), subcutaneous
metrazole (sc. MET) and a rotarod test for neurolo-
gical toxicity (TOX). 
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Comp. III-IX n=0
No. III IV V VI VII VIII IX
R 2-CH3 2-CH3 5-Cl 3-Cl 3-CF3 4-CH3 4-Cl 4-F
Comp. X-XVI n=1
No. X XI XII XII XIV XV XVI
R H 2-Cl 2-OCH3 4-Cl 4-F 4-CH3 4-OCH3








III C16H15O2N1 41 75.63 5.97 5.53 0.78 A
253.30 133-135 75.87 6.15 5.43 0.24 B
IV C16H14O2N1Cl1 47 66.79 4.90 4.87 0.79 A
287.75 208-210 66.52 5.00 4.78 0.26 B
V C15H12O2N1Cl1 48 65.82 4,42 5.12 0.78 A
273.72 177-179 65.52 4.71 5.03 0.28 B
VI C16H12O2N1F3 43 62.54 3.94 4.56 0.79 A
307.28 198-200 62.52 4.13 4.46 0.20 B
VII C16H15O2N1 50 75.87 5.97 5.53 0.74 A
253.30 169-171 75.71 6.27 5.49 0.39 B
VIII C15H12O2N1Cl1 41 65.82 4.42 5.12 0.67 A
273.72 169-171 66.01 4.69 5.06 0.25 B
IX C15H12O2N1F1 46 70.03 4.40 5.44 0.72 A
257.27 187-189 69.79 4.86 5.39 0.32 B
X CH15O2N1 48 75.87 5.97 5.53 0.81 A
253.30 90-91 75.94 6.16 5.50 0.40 B
XI C16H14O2N1Cl1 39 66.79 4.90 4.87 0.86 A
287.75 142-144 66.76 5.12 4.83 0.36 B
XII C17H17O3N1 42 72.07 6.05 4.94 0.81 A
283.33 143-144 72.00 6.32 4.89 0.25 B
XIII C16H14O2N1Cl1 48 66.79 4.90 4.87 0.74 A
287.75 105-107 66.69 5.09 4.80 0.37 B
XIV C16H14O2N1F1 40 70.84 5.20 5.16 0.84 A
271.23 93-95 70.50 5.46 5.03 0.36 B
XV C17H17O2N1 43 76.38 6.41 5.24 0.86 A
267.33 110-112 76.44 6.50 5.14 0.36 B
XVI C17H17O3N1 45 72.07 6.05 4.94 0.76 A
283.33 119-121 72.23 6.25 4.92 0.29 B
a Yields calculated from acetic anhydride.
b Solvents : A- chloroform : acetone (9 : 1), B- ethyl acetate : n-hexane (3 : 7)
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The MES test is a model for generalized tonic-
-clonic seizures. In this test, an electrical stimulus of
0.2 s in duration (50 mA in mice at 60 Hz) is delive-
red via corneal electrodes. Mice are tested for 0.5
and 4 h with the following doses: 30, 100, 300
mg/kg of tested compound.
The sc. MET is a model for compounds that ra-
ise a seizure threshold. In sc. MET test a dose of me-
trazole (85 mg/kg in mice) was administrated subcu-
taneously. This produces clonic seizures during
a period of least 5 seconds in 97% of tested animals.
The tested compounds are administrated intraperito-
neally, suspended in 0.5% methylcellulose at doses
of 30, 100, 300 mg/kg.
Neurotoxicity, induced by tested compounds,
is detected in mice using a rotarod test. Untreated
control mice, when placed on a 6 r. p. m. rotation rod
can maintain their equilibrium for a prolonged time.
Neurotoxicity is indicated by the inability of mouse
maintaining equilibrium for one min in each of the
three successive trials. 
Phase I is a qualitative assay involving a small
number of mice (1-4). The compounds were classi-
fied into the following categories: anticonvulsant ac-
tivity at 100 mg/kg or less (class 1), anticonvulsant
activity at doses higher than 100 mg/kg (class 2),
compounds inactive at 300 mg/kg (class 3). The re-
sults are shown in Tables 4 and 5.
RESULTS
As part of our study, we investigated the con-
version of the aryl system of the earlier obtained
compounds I and II to the norbornane moiety, as
well as the substitution mode in the aryl ring of N-
-benzyl- and N-phenyl-bicyclo [2.2.1] hept-5-ene-
-2,3-dicarboximides. Taking account of our earlier
experiments, introduction of substituents into 2 po-
sition of the aryl ring should enhance the activity.
Such an effect was observed for both electron-do-
nating 2-CH3 [III] and electron-attracting 2-Cl [XI]
substituents which were active at a dose of 100
mg/kg (2/3 and 3/3 of the animals protected after
0.5 h) in the MES test. Compound XII with the
2-OCH3 group was also ascribed to ASP class 1, but
as the only one of the whole series, was active at
a dose of 100 mg/kg (1/5 of the animals protected
after 0.5 h) in the sc. MET test, and inhibited elec-
Table 2. 1H NMR data of compounds III-IX
No. R 1H NMR δ(ppm) / CDCl3
III 2-CH3 1.62-1.87 (2H, m, Ha), 2.12-2.16 (3H, d, -CH3, J=9.35Hz), 3.48-3.56
(4H, m, 2Hb, 2Hc), 6.33-6.35 (2H, t, Hd, J=1.65Hz), 6.88-7.02 (1H, dd, Hg,
J=7.56Hz), 7.23-7.36 (3H, m, Hf, Hh, Hi)
IV 2-CH3 5-Cl 1.62-1.87 (2H, m, Ha), 2.08-2.17 (3H, d, -CH3, J=9.07Hz), 3.48-3.56 (4H, m,
2Hb, 2Hc), 6.32-6.36 (2H, dt, Hd, J=1.65 Hz), 6.87-7.04 (1H, dd, Hg, 
J=2.20Hz), 7.21-7.32 (2H, m, Hf, Hi)
V 3-Cl 1.60-1.85 (2H, m, Ha), 3.43-3.56 (4H, m, 2Hb 2Hc), 6.29-6.30 (2H, t, Hd, 
J=1.78 Hz), 7.05-7.12 (1H, m, Hg), 7.19-7.20 (1H, dd, Hh, J=1.37Hz),
7.30-7.42 (2H, m, He, Hi)
VI 3-CF3 1.64-1.86 (2H, m, Ha), 3.47-3.57 (4H, m, 2Hb, 2Hc), 6.30-6.32 (2H, t, Hd,
J= 1.92Hz), 7.38-7.39 (1H, d, Hg , J=1.37Hz), 7.41-7.47 (1H, m, Hh),
7.56-7.66 (2H, m, He, Hi)
VII 4-CH3 1.60-1.84 (2H, m, Ha), 2.39 (3H, s,-CH3), 3.42-3.55 (4H, m, 2Hb, 2Hc),
6.28-6.30 (2H, t, Hd, J=1.79Hz), 7.02-7.05 (2H, dd, Hf, Hh, J=1.94Hz),
7.24-7.29 (2H, d, He, Hi, J=7.97Hz)
VIII 4-Cl 1.61-1.84 (2H, m, Ha), 3.45-3.57 (4H, m, 2Hb, 2Hc), 6.27-6.29 (2H, t, Hd,
J=1.92Hz), 7.10-7.15 (2H, m, Hf, Hh), 7.40-7.45 (2H, m, He, Hi)
IX 4-F 1.62-1.85 (2H, m, Ha), 3.46-3.56 (4H, m, 2Hb, 2Hc), 6.28-6.29 (2H, t, Hd, 
J=1.78Hz), 7.11-7.17 (4H, m, arom.)
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trically provoked seizures (MES) at a dose of 300
mg/kg (1/1 of the animals protected after 0.5 h).
The introduction of a chloro substituent into posi-
tion -5 of compound III yielded an inactive deriva-
tive IV. Compounds with the 3-Cl [V], and the 3-
CF3 [VI] group were less active (ASP class 2), pro-
bably due to an unfavorable distance between the
electron-attracting atoms and carbonyl oxygen. As
anticipated, the introduction of substituents into po-
sition -4 of the aryl ring gave inactive compounds
[VII, IX, XV, XVI]. Surprisingly enough, an incre-
ased anticonvulsant activity (MES) was observed in
the case of the 4-Cl derivatives VIII and XIII,
which were potent at doses of 100 and 300 mg/kg
(2/3 and 1/1 of the animals protected after 4 h, re-
spectively) [VIII], and at a dose of 300 mg/kg (1/1
of the animals protected after 0.5 h) [XIII]. In the
series of N-benzyl derivatives, the unsubstituted
compound X and its 4-F analogue XIV were only
slightly active at a dose of 300 mg/kg (1/1 of the
animals protected after 0.5 and 4 h respectively) in
the MES test. 
In a neurological toxicity screening test, all the
inactive compounds [IV, VII, IX, XV and XVI] were
non-toxic at a dose of 300 mg/kg. The mice were una-
ble to grasp the rotarod after administration of compo-
unds X-XIV at a dose of 300 mg/kg after 0.5 h. Addi-
tionally, after administration of compounds with 3-
CF3 [VI], 4-Cl [XIII] and 4-F [XIV] substituents, the
animals had clonic seizures and muscle spasms.
In conclusion, our investigation has shown that
the replacement of the aryl ring in our earlier synthe-
sized 3-arylpyrrolidine-2,5-dione derivatives with
a norbornane moiety connected with the succinimi-
de at 3 and 4 carbon atoms causes deterioration of
their anticonvulsant properties, probably due to the
rigidity of the molecule. Surprisingly, of all the te-
sted N-phenyl- and N-benzyl-bicyclo [2.2.1] hept-5-
ene-2,3-dicarboximide derivatives [III-XVI], none
was more active than the previously obtained series
to which compounds I and II belong. In summary,
no additional studies with this group of N-substitu-
ted bicyclo [2.2.1] hept-5-ene-2,3-dicarboximides
are planned for in future.
Table 3. 1H NMR data of compounds X-XVI
No. R 1H NMR δ (ppm) / CDCl3
X H 1.52-1.74 (2H, m, Ha), 3.25-3.52 (4H, m, 2Hb, 2Hc), 4.52 (2H, s, -CH2-),
5.92-5.93 (2H, t, Hd, J=1.80Hz), 7.28-7.34 (5H, m, arom.)
XI 2-Cl 1.58-1.81 (2H, m, Ha), 3.34-3.51 (4H, m, 2Hb, 2Hc), 4.68 (2H, s, -CH2-),
6.14-6.16 (2H, t, Hd, J=1.92Hz), 7.19-7.23 (3H, m, Hg, Hh, Hi), 7.35-7.38
(1H, m, Hf)
XII 2-OCH3 1.56-1.79 (2H, m, Ha), 3.32-3.52 (4H, m, 2Hb, 2Hc), 3.86 (3H, s, -OCH3),
4.60 (2H, s, -CH2-), 6.10-6.12 (2H, t, Hd, J=1.79 Hz), 6.84-6.89 (2H, m, Hf, 
Hh), 7.07-7.10 (1H, dd, Hi, J=1.65Hz), 7.21-7.27 (1H, td, Hg, J=1.65Hz)
XIII 4-Cl 1.53-1.75 (2H, m, Ha), 3.27-3.52 (4H, m, 2Hb, 2Hc), 4.47 (2H, s, -CH2-),
5.91-5.92 (2H, t, Hd, J=1.78Hz), 7.26-7.28 (4H, m, arom.)
XIV 4-F 1.52-1.74 (2H, m, Ha), 3.26-3.52 (4H, m, 2Hb, 2Hc), 4.48 (2H, s, -CH2-),
5.89-5.90 (2H, t, Hd, J=1.92 Hz), 6.96-7.02 (2H, m, Hf, Hh), 7.30-7.36 (2H,
m, He, Hi)
XV 4-CH3 1.52-1.74 (2H, m, Ha), 2.34 (3H, s, -CH3), 3.26-3.52 (4H, m, 2Hb, 2Hc), 
4.48 (2H, s, -CH2-), 5.93-5.95 (2H, t, Hd, J=1.92Hz), 7.09-7.12 (2H, d, Hf, 
Hh, J=7.97Hz), 7.21-7.24 (2H, m, He, Hi)
XVI 4-OCH3 1.51-1.73 (2H, m, Ha), 3.25-3.40 (4H, m, 2Hb, 2Hc), 3.81 (3H, s, -OCH3), 
4.45 (2H, s, -CH2-), 5.90-5.91 (2H, t, Hd, J=1.78Hz), 6.80-6.85 (2H, d, Hf, 
Hh, J=8.80Hz), 7.27-7.29 (2H, m, He, Hi)
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Table 4. Anticonvulsant screening project (ASP) phase I test in mice for Nñphenyl bicyclo[2.2.1]hept-5-ene-2,3-dicarboximide derivatives
(III-IX)
Dose MESa sc.METb TOXc ASPd
Comp. mg/kg 0,5h 4h 0,5h 4h 0,5h 4h Class
30 0/1 0/1 0/1 0/1 0/4 0/2
III 100 2/3 0/3 0/1 0/1 0/8 0/4 1
300 1/1 0/1 0/1 0/1 1/4 0/2
30 0/1 0/1 0/1 0/1 0/4 0/2
IV 100 0/3 0/3 0/1 0/1 0/8 1/4 3
300 0/1 0/1 0/1 0/1 0/4 0/2
30 0/1 0/1 0/1 1/1 0/4 0/2
V 100 0/3 0/3 0/1 0/1 0/8 1/4 2
300 0/1 0/1 0/1 1/1 2/4 1/2
30 0/1 0/1 0/1 0/1 0/434 1/2
VI 100 0/3 0/3 0/1 1/1 3/823, 34 0/4 2
300 0/1 1/1 0/1 0/1 4/422, 23,34 2/234
30 0/1 0/1 0/1 0/1 0/4 0/2
VII 100 0/3 0/3 0/1 0/ 0/8 0/4 3
300 0/1 0/1 0/1 0/1 0/4 0/2
30 0/1 0/1 0/1 0/1 0/4 0/2
VIII 100 0/3 2/3 0/1 0/ 0/8 0/4 1
300 0/1 1/1 0/1 0/0 1/4 2/2
30 0/1 0/1 0/1 0/1 0/4 0/2
IX 100 0/3 0/3 0/1 0/ 0/8 0/4 3
300 0/1 0/1 0/1 0/1 0/4 0/2
a) Maximal electroshock test (number of animals protected/ number of animals tested); b) Subcutaneous metrazole test; c) Rotarod toxicity
(number of animals exhibiting toxicity/ number of animals tested). 
d) The classification are as follows: active at 100 mg/kg or less (class 1), anticonvulsant activity at a dose greater than 100 mg/kg (class 2),
inactive at 300 mg/kg (class 3). 
Response comments:3death following continuous seizure, 14unable to grasp rotarod, 22 continuous seizure activity; 23clonic seizures, 34muscle
spasms.
Table 5. Anticonvulsant screening project (ASP) phase I test in mice for Nñbenzyl bicyclo[2.2.1]hept-5-ene-2,3-dicarboximide derivatives
(X-XVI)
Dose MESa sc.METb TOXc ASPd
Comp. mg/kg 0,5h 4h 0,5h 4h 0,5h 4h Class
30 0/1 0/1 0/1 0/1 0/4 0/2
X 100 0/3 0/3 0/1 0/1 0/8 0/4 2
300 1/1 1/1 0/122 0/1 3/414,34 0/2
30 0/1 0/1 0/1 0/1 0/4 0/2
XI 100 3/3 0/3 0/1 0/1 0/8 0/4 1
300 1/1 1/1 0/1 0/1 3/414 0/2
30 0/1 0/1 0/1 0/1 0/4 0/2
XII 100 0/3 0/3 1/5 0/1 0/8 0/4 1
300 1/1 0/1 1/1 0/1 4/414 0/2
30 0/1 0/1 0/1 0/1 0/4 0/2
XIII 100 0/3 0/3 0/1 0/1 0/8 0/4 2
300 1/1 1/1 0/1 0/1 4/414, 23,34 0/2
30 0/1 0/1 0/1 0/1 0/4 0/2
XIV 100 0/3 0/3 0/1 0/1 1/814 0/4 2
300 1/1 1/1 0/122 0/1 4/414, 23,34 0/2
30 0/1 0/1 0/1 0/1 0/4 0/2
XV 100 0/3 0/3 0/1 0/1 0/8 0/4 3
300 0/1 0/1 0/1 0/1 0/4 0/2
30 0/1 0/1 0/1 0/1 0/4 0/2
XVI 100 0/3 0/3 0/1 0/1 0/8 0/4 3
300 0/1 0/1 0/1 0/1 0/4 0/2
a), b), c), d), and response comments see Table 4.
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